Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026
Key Highlights
- ➤Virtue Trial enrolling approximately 740 patients versus AGENT paclitaxel-coated balloon
- ➤SABRE three-year target lesion failure rate reached 14.3% in all treated patients
- ➤Virtue SAB presentation scheduled for TCT 2026 on November 1
- ➤Orchestra BioMed (OBIO) will present Virtue SAB’s differentiated sirolimus-delivery approach
- ➤Medtronic (MDT) collaborates with Orchestra BioMed on AVIM Therapy development and commercialization
Expert Statements
Allen Jeremias, MD, Co-Principal Investigator of the Virtue Trial and Director of Interventional Cardiology Research and Director of the Cardiac Catheterization Laboratory at St. Francis Hospital & Heart Center
“Patients with coronary in-stent restenosis frequently face renewed narrowing of a previously treated artery that requires another intervention. We need more durable treatment options that better address this recurring problem without adding another permanent layer of metal inside the artery. Virtue SAB offers the potential to achieve better vessel healing following intervention through optimized sirolimus drug delivery via balloon-based infusion. The Virtue Trial is an opportunity to determine whether this novel approach can translate into meaningful clinical benefit for patients. I look forward to sharing this innovative technology and the pivotal IDE trial design with the TCT community.”
* Presentation will highlight Virtue SAB’s fundamentally different approach of infusing a large liquid volume of proprietary extended-release SirolimusEFR™ directly into and throughout the vessel wall. * Virtue SAB’s mechanism is designed to achieve sustained, transmural sirolimus tissue levels substantially exceeding those achieved by drug-eluting stents and drug-coated balloons. * The Virtue Trial, a pivotal, head-to-head, randomized controlled IDE trial of Virtue SAB versus a commercially available drug-coated balloon in coronary in-stent restenosis, is currently enrolling. NEW HOPE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, today announced that its Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) will be featured in a presentation at Transcatheter Cardiovascular Therapeutics (“TCT”) 2026. TCT, the Cardiovascular Research Foundation’s annual scientific symposium and the world’s premier educational meeting in interventional cardiovascular medicine, will take place October 31–November 3, 2026, at the San Diego Convention Center in San Diego, California.
Get started
Create a free account to read the full story.